News

Filter

Current filters:

Rare diseasesKalydeco

1 to 9 of 23 results

Royalty Pharma pays $3.3 billion for CFF royalty rights to Kalydeco

19-11-2014

Royalty Pharma says it has acquired royalties on Vertex Pharmaceuticals' cystic fibrosis treatments,…

BiotechnologyFinancialKalydecoRare diseasesRoyalty PharmaVertex Pharmaceuticals

Australian PBS listing for Kalydeco and Soliris

Australian PBS listing for Kalydeco and Soliris

27-10-2014

Kalydeco (ivacaftor) and Soliris (eculizumab) – new treatments for cystic fibrosis (CF) and hemolytic…

Alexion PharmaceuticalsAustraliaFinancialHealthcareKalydecoPharmaceuticalRare diseasesSolirisVertex Pharmaceuticals

FDA advisory backs expanded use of Vertex’ CF drug

22-10-2014

There was good news for US biotech firm Vertex Pharmaceuticals yesterday, as a US Food and Drug Administration…

BiotechnologyKalydecoRare diseasesRegulationUSAVertex Pharmaceuticals

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP

27-06-2014

Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

Vertex leaps on positive Ph III results with lumacaftor

Vertex leaps on positive Ph III results with lumacaftor

24-06-2014

US biotech firm Vertex Pharmaceuticals saw its share price rocket nearly 52% to $101.20 in extending…

BiotechnologyBusiness FinanceCystic fibrosisHealth Medical PharmaKalydecolumacaftorMedicinePhenolsRare diseasesRegulationResearchVertex Pharmaceuticals

FDA backs Kalydeco for eight additional mutations that cause cystic fibrosis

22-02-2014

The US Food and Drug Administration approved biotech firm Vertex Pharmaceuticals’ supplemental New…

BiotechnologyKalydecoNorth AmericaRare diseasesRegulationUSAVertex

Vertex outlines progress on cystic fibrosis drug development

17-10-2013

USA-based biotech firm Vertex Pharmaceuticals provided a comprehensive update on recent progress in its…

BiotechnologyKalydecolumacaftorRare diseasesResearchVertexVX-661

Vertex shoots up 60% on positive trial results for Kalydeco and VX-661

22-04-2013

US biotech firm Vertex Pharmaceuticals' (Nasdaq: VRTX) shares rocketed 60% to $84.87 Friday morning after…

BiotechnologyKalydecoRare diseasesResearchVertexVX-661

1 to 9 of 23 results

COMPANY SPOTLIGHT

Menarini

Back to top